

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
LOMACEN.015C5APPLICATION NO.  
10/661,336INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
William J. WechterFILING DATE  
September 12, 2003GROUP  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
UR	1	5,106,630	04/21/92	Bricker <i>et al.</i>			
UR	2	5,422,393	06/06/95	Bricker <i>et al.</i>			
UR	3	6,083,982	07/04/00	Wechter <i>et al.</i>			
UR	4	6,150,402	11/21/00	Wechter <i>et al.</i>			
UR	5	6,555,575	04/29/00	Wechter			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES. ETC.)	

S:\DOCS\MCK\MCK-9577.DOC  
082504

EXAMINER	<i>Chad Petersen</i>	DATE CONSIDERED	8/24/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. LOMACEN.015C5	APPLICATION NO. 10/661,336
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT William J. Wechter  FILING DATE September 12, 2003	
		GROUP 1614	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
UB	1	2002/0107207 A1	08/08/02	Sanders et al.			
UB	2	2002/0156024 A1	10/24/02	Sanders et al.			
UB	3	2004/0097431 A1	05/20/04	Sanders et al.			
OB	4	6,417,223 B1	07/09/02	Sanders et al.			
UB	5	6,703,384 B2	03/09/04	Sanders et al.			


## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S:\DOCS\IES\FESF-7873.DOC  
060804

EXAMINER <i>Chris Johnson</i>	DATE CONSIDERED 8/24/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
LOMACEN.015C5APPLICATION NO.  
10/661,336INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
William J. WechterFILING DATE  
September 12, 2003

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
WE	1.	4,144,325	03/13/79	Voyt	424	59	
WE	2.	6,410,589	06/25/02	Wechter	514	548	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
WE	3.	0 350 913	01/17/90	EPO				

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
WR	4.	Isselbacher, et al., Ed's, Harrison's Principles of Internal Medicine, 13 <sup>th</sup> ed., Vol. 2, McGraw-Hill, New York, 1994.					

EXAMINER

DATE CONSIDERED

8/24/2004

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LOMACEN.015C5	APPLICATION NO. 10/661,338
	APPLICANT William J. Wechter			
	FILING DATE September 12, 2003		GROUP	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
UR	1.	4,321,270	03/23/82	Sundeen	424	267	
UR	2.	4,914,197	04/03/90	Yamamoto et al.	536	117	
UR	3.	5,139,796	08/18/92	Barkalow et al.	426	3	
UR	4.	5,200,214	04/06/93	Barkalow et al.	426	3	
UR	5.	5,270,060	12/14/93	Foster et al.	426	3	
UR	6.	5,739,156	04/14/98	Bissett	514	458	
UR	7.	6,048,891	04/11/00	Wechter	514	456	
UR	8.	6,242,479	06/05/01	Wechter	514	456	
UR	9.	6,426,362	07/30/02	Miller et al.	514	458	
UR	10.	2002/0040053	04/04/02	Kondo et al.	514	456	
UR	11.	2002/0132845	09/19/02	Miller et al.	514	458	
UR	12.	2002/0143049	10/03/02	Miller et al.	514	458	
UR	13.	2003/0013656	01/16/03	Wang et al.	514	17	
UR	14.	2003/0013657	01/16/03	Wang et al.	514	17	
UR	15.	2003/0013846	01/16/03	Wang et al.	530	330	
UR	16.	2003/0013847	01/16/03	Wang et al.	530	330	
UR	17.	2003/0022818	01/30/03	Wang et al.	514	6	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
UR	18.	0 326 987 A2		EPO				
UR	19.	0 413 668 A2		EPO				
UR	20.	WO 96/05191		PCT				


EXAMINER

*Wm J. Wechter*

DATE CONSIDERED

8/24/2006

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTO-449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
LOMACEN.015C5APPLICATION NO.  
10/661,338INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
William J. WechterFILING DATE  
September 12, 2003

GROUP

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
WR	21	WO 96/19215		PCT				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


	22	Beharka, et al., "Vitamin E Status and Immune Function," Methods in Enzymology, Vol. 282, pp. 247-263, 1997.
	23	Benaksas, et al., Life Sciences, 52:1045-54 (1993)
	24	Bottje et al., "Effect of Dietary dl-alpha-Tocopherol on tissue alpha- and Gamma- Tocopherol and Pulmonary Hypertension Syndrome (Ascites in Broilers," Poultry Science, 76:1506-12, Abstract Only (1997)
	25	Burnett, et al., "Mechanisms of Phytochemical Inhibition . . .," American Chemical Society Symposium Series, pp. 45-58, 1998.
	26	Campo, et al., <i>Free Radical Biology and Medicine</i> , "Reduction of Myocardial Infarct Size in rat by IRFI-048, a selective analogue of Vitamin E", Vol. 16, pp.427-435 (1994)
	27	Campo, et al., <i>Pharmacology</i> , "Protective Effects of IRF-016, a New Antioxidant Agent, in Myocardial Damage, following coronary artery occlusion and reperfusion in the rat", 48:157-166 (1994)
	28	Campo, et al., <i>Research Comm. in Chem. Pathology and Pharmacology</i> , "IRFI-016, a new radical scavenger, limits ischemic damage following coronary artery occlusion in rats", Vol. 76, No., pp.287-303, (1992)
	29	Christen et al., "gamma-Tocopheral Traps Mutagenic Electrophiles such as NO <sub>x</sub> and Complements alpha-Tocopheral: Physiological Implications," Proc. Natl. Acad. Sci., USA, 94(7):3217-22 (1997)
	30	Elson, Charles E., "Impact of Palm Oil on Experimental Carcinogenesis," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 39, pp. 533-45 (1993)
	31	Frei & Ames, "Relative Importance of Vitamine E in Antiperoxidative Defenses in Human Blood Plasma and Low-Density Lipoprotein (LDL)," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 10, pp. 131-39 (1993)
	32	Germano, Carl, <a href="http://www.solgar.com/nutrition_library/articles/tocotrienols.html">http://www.solgar.com/nutrition_library/articles/tocotrienols.html</a> , Posted 11/27/1997, 4 pgs., "Tocotrienols in Health & Disease: A Novel Antioxidant in the Treatment of Hypercholesterolemia and Cancer."
	33	Kantoci et al., "Endogenous Natriuretic Factors 6: The Stereochemistry of a Natriuretic gamma-Tocopherol Metabolite LLU-α," Journal of Pharmacology and Experimental Therapeutics, 282(2):648-656 (1997)
WR	34	Life Extension Foundation, <a href="http://lef.org/prod_desc/item564.html">http://lef.org/prod_desc/item564.html</a> , (1995-1999), 2 pgs., "Gamma E Tocopherol Formula."

EXAMINER

DATE CONSIDERED

Aug 24 2006

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

	FORM PTO-1448 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. LOMACEN.015C5	APPLICATION NO. 10/881,338
	APPLICANT William J. Wechter		
	FILING DATE September 12, 2003	GROUP	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
GR	35. Life Extension Foundation, <a href="http://lef.org/cgi-local/shop.pl/page=feb98_newproduct.html">http://lef.org/cgi-local/shop.pl/page=feb98_newproduct.html</a> , (1995-1999), 3 pgs., "Not all Vitamin E is Created Equal."
	36. McLaughlin & Weihrauch, "Vitamin E Content of Foods," Journal of the American Dietetic Association, 75:6547-665 (1979)
	37. Meydani, Mohsen, "Vitamin E," The Lancet, 345:170-175 (1995)
	38. Meydani, S. & R. Tengerdy, "Vitamin E and Immune Response," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 40, pp. 549-561 (1993)
	39. Murray, David E. et al., "Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic $\gamma$ -Tocopherol Metabolite LLU- $\alpha^1$ ," The Journal of Pharmacology and Experimental Therapeutics, Vol. 282, pp. 657-662 (1997)
	40. Nando.net & The Associated Press, <a href="http://www.nando.net/newsroom/ntr/health/033197/health12-4931.html">http://www.nando.net/newsroom/ntr/health/033197/health12-4931.html</a> , 1997, 2 pgs., "Too Much Vitamin E Can be Harmful."
	41. Odeleve, et al., "The Potential Role of Vitamin E in the Treatment of Immunologic Abnormalities During Acquired Immune Deficiency Syndrome," Database Medline, 1991.
	42. Packer et al., "Significance of Vitamin E for the Athlete," Vitamine E in Health and Disease, Packer & Fuchs eds, (1993) Chapter 34, pp. 465-71
	43. Richardson et al., "Adhesion of Human Platelets Inhibited by Vitamin E," Vitamine E in Health and Disease, Packer & Fuchs eds, 1993, Ch. 24, pp. 297-311.
	44. Shigenaga et al., "Inflammation and NO <sub>x</sub> -induced Nitration: Assay for 3-nitrotyrosine by HPLC with Electrochemical Detection," Proc. Natl. Acad. Sci. USA, 94(7):3211-3216 (1997)
	45. Speek et al., "Vitamin E Composition of Some Speed Oils as Determined by High-Performance Liquid Chromatography with Fluorometric Detection," Journal of Food Science, 50:121-124 (1985)
	46. Stone, et al., "Tocopherols and the Etiology of Colon Cancer," Journal of the National Cancer Institute, Vol 89, pp. 1006-1014, 1997.
	47. The Merck Index, 11 <sup>th</sup> edition, published by Merck & Co., Inc. (NJ), 1989, citation 9418, pg. 1495.
	48. Wechter et al., "A New Endogenous Natriuretic Factor: LLU- $\alpha$ ," Proc. Natl. Acad. Sci. USA, 93:6002-6007 (1996)
	49. Weichet et al., "Studien in der Gruppe der Vitamine K und E vi. Über die Darstellung von 2, 5, 7, 8, - Tetramethyl-2-( $\beta$ -Carboxy-Äthyl)-6-Hydroxychroman und Dessen Oxydationsprodukt," Collection Czechoslov. Chem. Commun., 24:1689-1694 (1959) No Translation
	50. Official Monographs, "Vitamin E," "Vitamin E Preparation," and "Vitamin E Capsules," USP 23, pp. 1631-1633
	51. "Myraid Genetics Plans to Launch the First Genetic Test for High Blood Pressure," Genetic Engineering News, pg. 27 (1997)
WJ	52. Yarita, et al., "Supercritical Fluid Chromatographic Determination of Cholesterol and Cholesteryl Esters in Serum on ODS-Silica Gel Column," Journal of Chromatography A., Vol. 679, pp. 329-334, 1994.

EXAMINER	<i>John F. ...</i>	DATE CONSIDERED	<i>Apr 24 2006</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			